$2.31
▲ +$0.04
(+1.76%)
Vol 344K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$319.7M
ROE
-6.9%
Margin
-1.7%
D/E
56.85
Beta
1.77
52W
$2–$6
Wall Street Consensus
10 analysts · Apr 20261
Strong Buy
8
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $0.00 | $0.01 | +$0.01 |
| Dec 2025 | $0.00 | $-0.56 | $-0.56 |
| Sep 2025 | $0.00 | $0.01 | +$0.01 |
| Jun 2025 | $-0.04 | $-0.04 | $0.00 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $138.3M | $142.5M | $137.8M | $149.7M | $164.0M |
| Net Income | — | -$4.7M | -$2.8M | -$2.9M | $598K | -$45.6M |
Fundamentals Trend
| Metric | 2025-07-31 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -6.9% | -6.8% | -6.9% | -6.9% | -6.9% | -6.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 0.4% | -1.8% | -1.7% | -1.7% | -1.7% | -1.7% |
| Gross Margin | 26.8% | 25.8% | 25.8% | 25.8% | 25.8% | 25.8% |
| D/E Ratio | 56.85 | 45.28 | 56.85 | 56.85 | 56.85 | 56.85 |
| Current Ratio | 1.85 | 1.57 | 1.85 | 1.85 | 1.85 | 1.85 |
Key Ratios
ROA (TTM)
-4.0%
P/S (TTM)
0.56
P/B
2.2
EPS (TTM)
$-0.12
CF/Share
$-0.40
Rev Growth 3Y
+42.3%
52W High
$5.59
52W Low
$2.37
$2.37
52-Week Range
$5.59
Financial Health
Free Cash Flow
$1.2M
Net Debt
$101.0M
Cash
$47.9M
Total Debt
$148.9M
As of Oct 31, 2025
How does HITI compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
HITI valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.6
▼
89%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
2.2
▲
4%
above
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
HITI profitability vs Pharmaceuticals peers
ROE
-6.9%
▲
87%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
-1.7%
▲
96%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
25.8%
▼
62%
below
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
-4.0%
▲
89%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
HITI financial health vs Pharmaceuticals peers
D/E ratio
56.9
▲
3592%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.9
▼
45%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.8
▲
88%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
HITI fundamentals radar
HITI
Peer median
Industry
HITI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
HITI vs peers: key metrics
Latest News
No related news yet